Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma.

Literature DB >> 17657213

PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma.

J Abubaker, P P Bavi, S Al-Harbi, A K Siraj, F Al-Dayel, S Uddin, K Al-Kuraya.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2007 PMID： 17657213 DOI： 10.1038/sj.leu.2404873

Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528

Keyword Cloud
Cited

× No keyword cloud information.

47 in total

Review 1. Oncogenic mutations of PIK3CA in human cancers.

Authors: Yardena Samuels; Todd Waldman
Journal: Curr Top Microbiol Immunol Date: 2010 Impact factor: 4.291

2. Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL.

Authors: Yihui Ma; Pengyu Zhang; Yi Gao; Huijie Fan; Mingzhi Zhang; Jingjing Wu
Journal: Int J Clin Exp Pathol Date: 2015-11-01

Review 3. Targeting the B cell receptor pathway in non-Hodgkin lymphoma.

Authors: Kelly Valla; Christopher R Flowers; Jean L Koff
Journal: Expert Opin Investig Drugs Date: 2018-06-07 Impact factor: 6.206

Review 4. Advances in targeted therapy for malignant lymphoma.

Authors: Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal: Signal Transduct Target Ther Date: 2020-03-06

5. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.

Authors: Jennifer R Brown; Mehdi Hamadani; John Hayslip; Ann Janssens; Nina Wagner-Johnston; Oliver Ottmann; Jon Arnason; Hervé Tilly; Michael Millenson; Fritz Offner; Nashat Y Gabrail; Siddhartha Ganguly; Sikander Ailawadhi; Siddha Kasar; Arnon P Kater; Jeanette K Doorduijn; Lei Gao; Joanne J Lager; Bin Wu; Coumaran Egile; Marie José Kersten
Journal: Lancet Haematol Date: 2018-03-14 Impact factor: 18.959

6. miR-19 is a key oncogenic component of mir-17-92.

Authors: Virginie Olive; Margaux J Bennett; James C Walker; Cong Ma; Iris Jiang; Carlos Cordon-Cardo; Qi-Jing Li; Scott W Lowe; Gregory J Hannon; Lin He
Journal: Genes Dev Date: 2009-12-15 Impact factor: 11.361

7. Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1/beta-catenin genes in human herpesvirus 8-associated primary effusion lymphoma.

Authors: Emmanuelle Boulanger; Agnès Marchio; Saw-See Hong; Pascal Pineau
Journal: Haematologica Date: 2009-07-16 Impact factor: 9.941